文献速递骨软组织肉瘤与黑色素瘤

Risvutatug rezetecan对比吉西他滨联合多西他赛治疗复发/难治性晚期骨肉瘤:ARTEMIS-011 III期试验主要结果

Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.
PubMed 文献 · Ann Oncol · 2026-10-26

ARTEMIS-011是一项多中心、开放标签、随机III期试验,在中国≥2线系统治疗后的复发/难治性骨肉瘤患者中比较B7-H3靶向抗体偶联药物Ris-Rez与吉西他滨联合多西他赛(GD)。Ris-Rez组BICR评估的中位PFS为5.5个月,GD组为1.4个月(HR 0.33,95%CI 0.20-0.55,P<0.0001);OS数据尚未成熟(HR 0.51,95%CI 0.21-1.23),安全性总体可控。

要点

  • Ris-Rez较GD显著改善BICR评估的PFS(5.5 vs 1.4个月,HR 0.33)。
  • OS数据未成熟,HR 0.51(95%CI 0.21-1.23),呈数值获益趋势。
  • ≥3级TRAE发生率93% vs 83%,以血液学毒性为主,需剂量调整与支持治疗。

核心结论

  • 在复发/难治性晚期骨肉瘤中,Ris-Rez较GD显著改善BICR评估的PFS,并呈OS数值改善趋势,安全性总体可控。

研究设计与样本

  • 多中心、开放标签、随机III期ARTEMIS-011试验,纳入≥12岁、≥2线系统治疗后复发/难治性骨肉瘤中国患者。
  • 患者按2:1随机接受Ris-Rez 12.0 mg/kg或吉西他滨联合多西他赛(GD),每3周一次,按年龄和肺转移分层。
  • 主要终点为BICR评估的PFS,次要终点包括OS和安全性;Ris-Rez组80例,GD组42例,中位随访7.1个月。

主要发现

  • BICR评估的中位PFS:Ris-Rez组5.5个月 vs GD组1.4个月(HR 0.33,95%CI 0.20-0.55,P<0.0001)。
  • OS数据未成熟,HR 0.51(95%CI 0.21-1.23)。
  • 中位治疗持续时间Ris-Rez组4.5个月 vs GD组1.5个月;无治疗相关不良事件导致死亡。

关键数值与推荐

  • ≥3级TRAE发生率:Ris-Rez组93% vs GD组83%;严重TRAE:64% vs 29%,以血液学毒性为主。
  • 因TRAE剂量下调:Ris-Rez组71% vs GD组26%;永久停药少见(3.8% vs 2.4%)。
  • 中位年龄21岁(IQR 17-34),青少年(12至<18岁)31例(25%)。

临床怎么用

  • 对于≥2线治疗失败的复发/难治性晚期骨肉瘤患者,Ris-Rez可作为新的治疗选择。
  • 用药期间需重点监测血液学毒性,及时进行剂量调整和支持治疗。
  • OS获益尚待更长期随访确认,目前PFS为主要疗效依据。

局限性

  • OS数据未成熟,随访时间较短(中位7.1个月)。
  • 开放标签设计,样本量有限(Ris-Rez组80例,GD组42例)。
  • 研究仅纳入中国患者,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with relapsed/refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. Herein, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase 3 trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Chinese patients with R/R osteosarcoma after ≥2 prior lines of systemic treatment. PATIENTS AND METHODS: Patients (≥12 years) were randomized 2:1 to Ris-Rez 12.0 mg/kg or gemcitabine plus docetaxel (GD), every 3 weeks, stratified by age and lung metastasis. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR); secondary endpoints included overall survival (OS) and safety. RESULTS: At data cutoff (June 17, 2026), 80 patients were treated with Ris-Rez and 42 with GD; median follow-up was 7.1 months. Median age was 21 years (IQR, 17-34) with 31 (25%) adolescents (12 to <18 years). BICR-assessed PFS significantly improved with Ris-Rez compared with GD (median, 5.5 vs 1.4 months; HR, 0.33; 95% CI, 0.20-0.55; P<0.0001). OS data were immature, with a HR of 0.51 (95% CI, 0.21-1.23). With longer treatment duration with Ris-Rez than GD (median, 4.5 vs 1.5 months), adverse events (AEs) were reported in all patients. No treatment-related AEs (TRAEs) led to death. Grade ≥ 3 TRAEs occurred in 93% of patients with Ris-Rez and 83% with GD, and serious TRAEs in 64% versus 29%, which were predominantly hematologic. TRAEs led to dose reductions in 71% versus 26% of patients with Ris-Rez versus GD, respectively, and permanent discontinuation was infrequent (3.8% vs 2.4%). CONCLUSIONS: In ARTEMIS-011, Ris-Rez demonstrated a statistically significant and clinically meaningful improvement in BICR-assessed PFS compared to GD, alongside a numerical trend toward improved OS and manageable safety profile with dose modifications and supportive care, offering a promising new treatment option for patients with R/R advanced osteosarcoma.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Xie L, Yao W, Hua Y, et al. Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial. Ann Oncol. 2026. PMID: 42933637. doi:10.1016/j.annonc.2026.10.1284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。